imeglimin
Trade name: Twymeeg
Small moleculeexperimental
Imeglimin is an oral anti-diabetic medication. It was approved for use in Japan in June 2021. — Wikipedia
Clinical trial activity
7 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
1
Phase 3
0
Phase 4
1
Earliest trial started Jan 1, 2013 (NCT01951235)
Timeline
Indications
Approved for
Mechanism of action
- Unspecified targetOTHER
Modulates mitochondrial respiratory chain and ROS
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Loading structure…
SMILES
C[C@H]1N=C(N(C)C)N=C(N)N1- Mol. weight
- 155.21 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaImeglimin ↗
- ChEMBLCHEMBL4297514 ↗
Also known as
- imeglimin
- imeglimin
- imeglimin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05366868 | Phase 4 | May 26, 2022 | National Center for Global Health and Medicine, Sumitomo |
| NCT03802786 | Phase 1 | Nov 6, 2018 | Poxel SA |
| NCT03646331 | Phase 1 | Aug 30, 2018 | Poxel SA |
| NCT03618316 | Phase 1 | Jun 19, 2018 | Poxel SA |
| NCT02924337 | Phase 1 | Sep 1, 2016 | Poxel SA |
| NCT02373150 | Phase 1 | Feb 1, 2015 | Poxel SA |
| NCT01951235 | Phase 2 | Jan 1, 2013 | Pauls Stradins Clinical University Hospital, Poxel SA |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Poxel SA | For profit | 6 | 6 | 2 | 2013 |
| National Center for Global Health and Medicine | Government | 1 | 1 | 1 | 2022 |
| Pauls Stradins Clinical University Hospital | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Sumitomo | For profit | 1 | 0 | 1 | 2022 |
4 organizations
Page 1 / 1